Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1995 1
1997 1
1999 1
2000 7
2001 7
2002 4
2003 13
2004 32
2005 51
2006 69
2007 91
2008 72
2009 44
2010 36
2011 22
2012 18
2013 9
2014 18
2015 9
2016 4
2017 4
2018 5
2019 4
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 18402899

468 results

Results by year

Filters applied: . Clear all
Page 1
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; TNT (Treating to New Targets) Investigators. Shepherd J, et al. J Am Coll Cardiol. 2008 Apr 15;51(15):1448-54. doi: 10.1016/j.jacc.2007.11.072. J Am Coll Cardiol. 2008. PMID: 18402899 Free article. Clinical Trial.
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.
Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; Treating to New Targets Investigators. Shepherd J, et al. Clin J Am Soc Nephrol. 2007 Nov;2(6):1131-9. doi: 10.2215/CJN.04371206. Epub 2007 Oct 17. Clin J Am Soc Nephrol. 2007. PMID: 17942759 Clinical Trial.
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. LaRosa JC, et al. N Engl J Med. 2005 Apr 7;352(14):1425-35. doi: 10.1056/NEJMoa050461. Epub 2005 Mar 8. N Engl J Med. 2005. PMID: 15755765 Free article. Clinical Trial.
Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H; Treating to New Targets (TNT) Steering Committee and Investigators. LaRosa JC, et al. Am J Cardiol. 2007 Sep 1;100(5):747-52. doi: 10.1016/j.amjcard.2007.03.102. Epub 2007 Jun 14. Am J Cardiol. 2007. PMID: 17719314 Clinical Trial.
Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH; CARDS Investigators. Colhoun HM, et al. Am J Kidney Dis. 2009 Nov;54(5):810-9. doi: 10.1053/j.ajkd.2009.03.022. Epub 2009 Jun 21. Am J Kidney Dis. 2009. PMID: 19540640 Clinical Trial.
468 results